ANDA 75626, held by Apotex. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 75626 (Ketorolac Tromethamine), held by Apotex, was first approved by FDA on Jul 24, 2001, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 24, 2001 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine30MG/ML ยท injectable;injection | Ketorolac Tromethamine | Discontinued |
| Nov 21, 2024 | Supplement 16Labeling ยท Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 14Labeling ยท Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 15Labeling ยท Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 13Labeling ยท Standard review | Approved | None posted |
| May 9, 2016 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| Oct 20, 2004 | Supplement 5Labeling | Approved | None posted |
| Nov 20, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Jul 24, 2001 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters